Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Dissecting acute neuronal responses to glioblastoma using a dual-interface human iPSC neuronal culture platform.

Acta neuropathologica communications·2026

Same author

MGMTai: O6-methylguanine-DNA methyltransferase (<i>MGMT</i>) methylation prediction in isocitrate dehydrogenase (<i>IDH</i>)-wild type glioblastoma to direct temozolomide therapy.

Neuro-oncology advances·2026

Same author

Erratum: Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

Guidelines for Seizure Prophylaxis in Patients Undergoing Supratentorial Neurosurgery: A Statement for Healthcare Professionals from the Neurocritical Care Society.

Neurocritical care·2026

Same author

Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

Boron Neutron Capture Therapy for High-Grade CNS Tumors: Mechanisms, Carriers, and Clinical Progress: A Narrative Review.

International journal of molecular sciences·2026

Search research articles

Related Experiment Video

Updated: Oct 17, 2025

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Targeted Therapy for BRAF Mutant Brain Tumors.

Appaji Rayi¹, Iyad Alnahhas², Shirley Ong³

¹Department of Neurology, Charleston Area Medical Center, Charleston, WV, USA.

Current Treatment Options in Oncology

|October 6, 2021

Summary

BRAF mutations in brain tumors, common in young adults, create unique vulnerabilities. Early detection via immunohistochemistry and sequencing is crucial for targeted therapy and managing treatment resistance.

More Related Videos

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Related Experiment Videos

Last Updated: Oct 17, 2025

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Area of Science:

Neuro-oncology
Molecular diagnostics
Genomic medicine

Background:

Brain tumors exhibit molecular heterogeneity, complicating targeted treatment strategies.
Gliomas harboring specific BRAF mutations present a unique therapeutic vulnerability, particularly in adolescents and young adults.
Accurate identification of BRAF mutations is critical for guiding effective treatment decisions.

Purpose of the Study:

To emphasize the importance of identifying BRAF mutations in brain tumors for targeted therapy.
To advocate for integrated diagnostic approaches for mutation detection.
To highlight the need for further research into resistance mechanisms and collaborative studies.

Main Methods:

Review of current understanding of molecular heterogeneity in brain tumors.
Discussion of the significance of BRAF mutations in specific glioma subtypes.
Proposal for combined immunohistochemical and sequencing methods for BRAF mutation detection.

Main Results:

BRAF mutations are a key actionable target in a subset of brain tumors, especially in younger populations.
Integrated diagnostic approaches are essential for timely and accurate mutation identification.
Further investigation into recurrent tumor resistance mechanisms is warranted.

Conclusions:

Targeted therapies for BRAF-mutated gliomas offer a promising avenue, particularly for adolescent and young adult patients.
Standardization of diagnostic methods, including immunohistochemistry and sequencing, is recommended for clinical practice.
Multicenter collaborative studies are vital for advancing the understanding and long-term management of these rare tumors.